I graduated! Check out my fancy new website here.
I completed my PhD in the Pharmaceutical Outcomes Research and Policy Program at the University of Washington. In 2015 I started a postdoctoral fellowship at Group Health Research Institute and the Fred Hutchinson Cancer Research Center, supported by a K12 institutional mentored career development award in Patient Centered Outcomes Research from the Agency for Healthcare Research and Quality (AHRQ).
My research interests include cancer outcomes & policy, development and implementation of decision analytical tools to help policymakers, patients, and healthcare providers in the face of uncertain and complex decisions, and the use of web-based technology to improve the dissemination and implementation of CER/PCOR methods and results.
My dissertation research explored the use of quantitative tools to aid in the selection and prioritization of publicly funded cancer clinical trials. Specifically, I leveraged promising advances in value of information (VOI) analyses and risk prediction to improve decision-making within a publicly funded cancer clinical trials cooperative group. This project developed, tested, and validated processes for rapidly estimating the expected risk and return for clinical trial proposals, and used these estimates to explore how a portfolio management framework could improve the efficiency of limited public resources. This work was supported by an R36 Award from AHRQ and a Doctoral Dissertation Improvement Grant from the National Science Foundation (NSF).
During graduate school, I also worked with Dr. David Veenstra on several projects related to the economic evaluation of whole genome/exome sequencing. You can read more about this work here and here. Before moving to Seattle, I worked as a biostatistician in Dr. Andrew Vickers’s research group at Memorial Sloan-Kettering Cancer Center, primarily focusing on the evaluation of novel biomarkers in prostate cancer screening and the clinical value of prediction models.